Clinically approved combination immunotherapy: Current status, limitations, and future perspective
-
Published:2022
Issue:
Volume:3
Page:118-127
-
ISSN:2590-2555
-
Container-title:Current Research in Immunology
-
language:en
-
Short-container-title:Current Research in Immunology
Author:
Lu Ligong,
Zhan Meixiao,
Li Xian-Yang,
Zhang Hui,
Dauphars Danielle J.,
Jiang Jun,
Yin Hua,
Li Shi-You,
Luo Sheng,
Li Yong,
He You-WenORCID
Reference117 articles.
1. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients;Batchelor;Cancer Cell,2007
2. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in Oncology;Benson;J. Natl. Compr. Cancer Netw.,2021
3. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma;Boige;Oncol.,2012
4. Biomarkers in hepatobiliary cancers: what is useful in clinical practice?;Boileve;Cancers,2021
5. Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients;Boucher;NPJ Precis. Oncol.,2021
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献